Biocon Shares

Foreign institutional investors sold shares worth Rs 561 crore on Tuesday while domestic institutional investors bought shares worth Rs 577 crore.

Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.

Biocon Q4 Results: Biocon's consolidated revenue increased 26 per cent in the fourth quarter of the fiscal 2020-21 to Rs 2,044 crore, compared to Rs 1,621 crore in the corresponding quarter last year.

On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.

Biocon shares may witness some action after the pharma company expanded its generic formulations portfolio, with the launch of tacrolimus capsules in the United States.

"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.

Stocks To Watch: Reliance Industries shares will be watched after the conglomerate said its subsidiary, Jio Platforms, received the subscription amount of Rs 33,737 crore from Google International LLC.

Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.

Biocon reported a net profit of Rs 120 crore for the quarter ended June 30, as against Rs 81.3 crore for the corresponding quarter a year ago.

Located in 447-C, 12th main, Koramangala, the bungalow is located in a leafy lane of a residential suburb that is now inundated with scores of restaurants, restro-bars and fitness centres, according to Flipkart Stories.

The Sensex ended 73 points lower at 35,103 while Nifty settled at 10,679, down 38 points.

Following the announcement, shares of the company opened on a bullish note and surged 14.20 per cent to touch an early high of Rs 510 on the Bombay Stock Exchange (BSE).

Biocon confirms that the US FDA has issued on establishment inspection report in relation to the cGMP (current Good manufacuring practice) inspection of its asceptic drug product facility

Biocon's Malaysia facility was inspected by the European Medicines Agency (EMA) in April 2017.

European drug regulators informed Biocon that the manufacturing facilities for two drugs needed to be re-inspected.

Foreign institutional investors sold shares worth Rs 561 crore on Tuesday while domestic institutional investors bought shares worth Rs 577 crore.

Biocon Share Price Today: On Friday, Biocon opened on the BSE at Rs 392, touching an intra day high of Rs 392 and an intra day low of Rs 380.55, in the trading session so far.

Biocon Q4 Results: Biocon's consolidated revenue increased 26 per cent in the fourth quarter of the fiscal 2020-21 to Rs 2,044 crore, compared to Rs 1,621 crore in the corresponding quarter last year.

On a standalone basis, Biocon's profit plunged 72 per cent annually to Rs 33 crore from Rs 121 crore during the same period last year.

Biocon shares may witness some action after the pharma company expanded its generic formulations portfolio, with the launch of tacrolimus capsules in the United States.

"The cost of the acquisition is Rs 5,91,61,730 for the acquisition of 26 per cent stake on a fully diluted basis in one or more tranches," the Bangalore-based Biocon said in a BSE filing.

Stocks To Watch: Reliance Industries shares will be watched after the conglomerate said its subsidiary, Jio Platforms, received the subscription amount of Rs 33,737 crore from Google International LLC.

Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.

Biocon reported a net profit of Rs 120 crore for the quarter ended June 30, as against Rs 81.3 crore for the corresponding quarter a year ago.

Located in 447-C, 12th main, Koramangala, the bungalow is located in a leafy lane of a residential suburb that is now inundated with scores of restaurants, restro-bars and fitness centres, according to Flipkart Stories.

The Sensex ended 73 points lower at 35,103 while Nifty settled at 10,679, down 38 points.

Following the announcement, shares of the company opened on a bullish note and surged 14.20 per cent to touch an early high of Rs 510 on the Bombay Stock Exchange (BSE).

Biocon confirms that the US FDA has issued on establishment inspection report in relation to the cGMP (current Good manufacuring practice) inspection of its asceptic drug product facility

Biocon's Malaysia facility was inspected by the European Medicines Agency (EMA) in April 2017.

European drug regulators informed Biocon that the manufacturing facilities for two drugs needed to be re-inspected.